Phio Pharmaceuticals
PHIO
1 hedge funds and large institutions have $4.98M invested in Phio Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
28% less capital invested
Capital invested by funds: $6.95M → $4.98M (-$1.97M)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$78K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$53K |
| 4 |
Goldman Sachs
New York
|
-$45K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$21K |
PHIO Hedge Fund Activity: Q2 2014 in Review
1 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2014, worth a combined $4.98M — down 28% from $6.95M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PHIO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Numeric Investors, exiting entirely with an estimated $1.4M sold.
- 1 institutional investor held Phio Pharmaceuticals (PHIO) as of Q2 2014, down from 2 in Q1 2014.
- Funds reported $4.98M of Phio Pharmaceuticals stock for Q2 2014, down 28% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q2 2014 and 1 closed out, a net change of -1 holder.
- The largest Phio Pharmaceuticals seller in Q2 2014 was Numeric Investors, an estimated $1.4M sold.
Based on aggregated 13F filings for Q2 2014.